 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C26H26N2O2 |
| Molar mass | 398.506 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
JWH-193 is a drug from theaminoalkylindole andnaphthoylindole families which acts as acannabinoidreceptoragonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has abinding affinity at the CB1 receptor of 6 nM, binding around seven times more tightly than the parent compoundJWH-200,[1] though with closer to twice the potency of JWH-200 in activity tests.
In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as JWH-193 areSchedule I Controlled Substances.[2]
A structural isomer of JWH-193 with the methyl group on the indole ring instead of the naphthoyl ring, was also found to be of similarly increased potency over JWH-200.[3][4]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
